Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, unveiled its new corporate name and website.
Eli Lilly and Company announced positive topline results from the QWINT-2 and QWINT-4 phase III clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections
Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca’s sipavibart (formerly AZD 3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID?19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population.